Elutia ELUT 深 沪
已收盘 10-09 16:00:00 美东时间
0.8231
-0.004
-0.51%
华盛通- 最 高0.8346
- 今 开0.82
- 成交量 2.00万股
- 最 低 0.7901
- 昨 收 0.8273
- 总市值 3.65万
- 52周最高 1.385
- 市盈率 静 --
- 换手率 0.05%
- 52周最低 0.50
- 委 比 -12.11%
- 总股本 4.43万
- 历史最高 18.20
- 量 比 0.05
- 振 幅 5.38%
- 历史最低 0.50
- 每 手 1
- 风险率 0.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Elutia Obtains $8M Payment from Boston Scientific; Co. Now Fully Funded into 2029
Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced it has received the full $8 million held in escrow in connection with the sale of its BioEnvelope business to Boston Scientific Corporation (NYSE:BSX). The payment was made follow...
10-02 04:51
Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th
Elutia Inc. announced that its executives, Dr. Randy Mills, Dr. Michelle Williams, and Matthew Ferguson, will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15–16, 2026, in New York City. The presentation will discuss Elutia's drug-eluting biomatrix technology aimed at addressing post-surgical infections in plastic and reconstructive surgeries. The presentation begins at 4:30 pm ET on September 15 and will be...
09-10 20:05
Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch
Elutia Inc. has completed the sale of its SimpliDerm® business to Cellution Biologics Inc. for up to $11 million, with $8 million paid at closing and up to $3 million in milestone payments over the next 18 months. The transaction allows Elutia to focus on developing and commercializing NXT-41x, an antibiotic-eluting biomatrix designed to prevent post-operative infections in the $1.5 billion U.S. plastic and reconstructive surgery market. FDA clea...
08-18 12:00
Elutia Q2 EPS $(0.17) Misses $(0.15) Estimate, Sales $2.427M Miss $2.900M Estimate
Elutia (NASDAQ:ELUT) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 34.62 percent increase over losses of $(0.26) per share from the same period last year. The company reported quarterly sales of $2.427 million which ...
08-14 04:11
Elutia Sheds Legacy Business to Chase $1.5 Billion Market Opportunity
Biomatrix technology innovator Elutia Inc. (NASDAQ:ELUT) on Friday agreed to divest its SimpliDerm human acellular dermal matrix operations. The buyer, Cellution Biologics Inc., will acquire the asset in a transaction that could be valued at a maximum of $11 million. This strategic sale allows the m...
07-18 00:07
Elutia Reports Q1 2026 Results: Full Earnings Call Transcript
Elutia (NASDAQ:ELUT) released first-quarter financial results and hosted an ear...
05-15 05:55
Elutia Q1 EPS $(0.17) Misses $(0.15) Estimate, Sales $3.114M Beat $3.000M Estimate
Elutia (NASDAQ:ELUT) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 19.05 percent increase over losses of $(0.21) per share from the same
05-15 04:14
Earnings Scheduled For May 14, 2026
Companies Reporting Before The Bell • Urban One (NASDAQ:UONEK) is expected to r...
05-14 19:11
Elutia Q4 EPS $(0.14), Inline, Sales $3.271M Miss $3.300M Estimate
Elutia (NASDAQ:ELUT) reported quarterly losses of $(0.14) per share which met the analyst consensus estimate. This is a 47.31 percent increase over losses of $(0.26) per share from the same period last year. The company
03-12 04:09
Earnings Scheduled For March 11, 2026
Companies Reporting Before The Bell • Sprinklr (NYSE:CXM) is estimated to repor...
03-11 19:11
